Literature DB >> 16808044

Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.

Evan L Riddle1, Annette E Fleckenstein, Glen R Hanson.   

Abstract

Methamphetamine (METH) is a powerful stimulant of abuse with potent addictive and neurotoxic properties. More than 2.5 decades ago, METH-induced damage to dopaminergic neurons was described. Since then, numerous advancements have been made in the search for the underlying mechanisms whereby METH causes these persistent dopaminergic deficits. Although our understanding of these mechanisms remains incomplete, combinations of various complex processes have been described around a central theme involving reactive species, such as reactive oxygen and/or nitrogen species (ROS and RNS, respectively). For example, METH-induced hyperthermia, aberrant dopamine(DA), or glutamate transmission; or mitochondrial disruption leads to the generation of reactive species with neurotoxic consequences. This review will describe the current understanding of how high-dose METH administration leads to the production of these toxic reactive species and consequent permanent dopaminergic deficits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16808044      PMCID: PMC3231576          DOI: 10.1007/bf02854914

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  75 in total

1.  Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors.

Authors:  Chiara Fiorentini; Fabrizio Gardoni; PierFranco Spano; Monica Di Luca; Cristina Missale
Journal:  J Biol Chem       Date:  2003-03-19       Impact factor: 5.157

Review 2.  Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges.

Authors:  Julie A Johnson; John J Lima
Journal:  Pharmacogenetics       Date:  2003-09

3.  Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.

Authors:  Verónica Sandoval; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

4.  Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.

Authors:  Evan L Riddle; Matthew K Topham; John W Haycock; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2002-08-02       Impact factor: 4.432

5.  A single methamphetamine administration rapidly decreases vesicular dopamine uptake.

Authors:  Jeffrey M Brown; Evan L Riddle; Verónica Sandoval; Raul K Weston; Jarom E Hanson; Michael J Crosby; Yvette V Ugarte; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

6.  Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism.

Authors:  Anthony J Baucum; Kristi S Rau; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci       Date:  2004-03-31       Impact factor: 6.167

7.  Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.

Authors:  Jannine G Truong; Kristi S Rau; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2003-08-08       Impact factor: 4.432

Review 8.  Impact of psychostimulants on vesicular monoamine transporter function.

Authors:  Annette E Fleckenstein; Glen R Hanson
Journal:  Eur J Pharmacol       Date:  2003-10-31       Impact factor: 4.432

Review 9.  Neuroprotection in idiopathic Parkinson's disease.

Authors:  Heinz Reichmann
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

Review 10.  Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress.

Authors:  Jeffrey M Brown; Bryan K Yamamoto
Journal:  Pharmacol Ther       Date:  2003-07       Impact factor: 12.310

View more
  83 in total

1.  Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.

Authors:  Gabriel C Loewinger; Michael V Beckert; Hugo A Tejeda; Joseph F Cheer
Journal:  Neuropharmacology       Date:  2012-01-25       Impact factor: 5.250

2.  Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine.

Authors:  Kimberly A Kelly; Diane B Miller; John F Bowyer; James P O'Callaghan
Journal:  J Neurochem       Date:  2012-08-03       Impact factor: 5.372

3.  Dysregulation of D₂-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure.

Authors:  Stephanie M Groman; Buyean Lee; Emanuele Seu; Alex S James; Karen Feiler; Mark A Mandelkern; Edythe D London; J David Jentsch
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

Review 4.  Towards nanomedicines for neuroAIDS.

Authors:  Vidya Sagar; Sudheesh Pilakka-Kanthikeel; Ravi Pottathil; Shailendra K Saxena; Madhavan Nair
Journal:  Rev Med Virol       Date:  2014-01-07       Impact factor: 6.989

5.  Differential effects of environment-induced changes in body temperature on modafinil's actions against methamphetamine-induced striatal toxicity in mice.

Authors:  Mariana Raineri; Betina González; Celeste Rivero-Echeto; Javier A Muñiz; María Laura Gutiérrez; Carolina I Ghanem; Jean Lud Cadet; Edgar García-Rill; Francisco J Urbano; Veronica Bisagno
Journal:  Neurotox Res       Date:  2014-09-27       Impact factor: 3.911

6.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

7.  Methamphetamine enhances HIV infection of macrophages.

Authors:  Hao Liang; Xu Wang; Hui Chen; Li Song; Li Ye; Shi-Hong Wang; Yan-Jian Wang; Lin Zhou; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

8.  Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage.

Authors:  Rosilla F Bachmann; Yun Wang; Peixiong Yuan; Rulun Zhou; Xiaoxia Li; Salvatore Alesci; Jing Du; Husseini K Manji
Journal:  Int J Neuropsychopharmacol       Date:  2009-01-19       Impact factor: 5.176

Review 9.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

10.  The role of the neuropeptide somatostatin on methamphetamine and glutamate-induced neurotoxicity in the striatum of mice.

Authors:  Lauriaselle Afanador; Ina Mexhitaj; Carolyn Diaz; Dalila Ordonez; Lisa Baker; Jesus A Angulo
Journal:  Brain Res       Date:  2013-03-19       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.